Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02710942
Other study ID # PSO-EST-2014-9575
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2016
Est. completion date December 2016

Study information

Verified date October 2018
Source IWK Health Centre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal for this pilot study is to assess the acceptability of two online self-guided programs for migraines. The programs are part of the investigators' collection of "my Wireless Headache Interventions" (myWHI). The Specialized Program for Headache Reduction (SPHERE) is a program that teaches cognitive and behavioural skills/techniques to help manage headaches. The PeRsonalized Intervention for Self-Management of Migraine (PRISM) helps users to discover their headache triggers and provides recommendations for managing them. This pilot will also assess the feasibility of the study protocol to inform a full scale randomized controlled trial (RCT).


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender All
Age group 14 Years to 35 Years
Eligibility Inclusion Criteria:

- aged 14-35 years

- fluent in the English language (i.e., speaking, reading and writing);

- suffer from headaches for a minimum of one year

- stable pattern of headache symptoms (e.g., headache frequency, severity, location of pain, symptoms associated with headache) for the past 6 months

- suffer from migraine headaches as indicated with a score of 2 and above on the ID Migraine

- use the Smartphone for activities other than texting and calling (e.g., email, Facebook)

- have daily Internet access from their Smartphone

- minimum of four headache days during 4 weeks of using an electronic headache diary

Exclusion Criteria:

- health care professional has not ruled out any underlying medical condition related to their headaches (e.g., head trauma, meningitis)

- are pregnant, planning to get pregnant (in the next 4 to 6 months), or breastfeeding

- have an impairment which compromises their ability to give informed consent

- having been diagnosed with psychosis and/or schizophrenia

- they complete less than 50% of daily entries (i.e., less than 14 daily entries) in an electronic headache dairy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
SPHERE

PRISM


Locations

Country Name City State
Canada IWK Health Centre Halifax Nova Scotia

Sponsors (1)

Lead Sponsor Collaborator
IWK Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average number of individuals who complete the online screening per month This is an exploratory study and we do not know how much time it will take for us to recruit our desired sample size. However, our maximum time frame is 1 year. After reaching our desired sample size for randomization
Primary Proportion of recruited participants who are eligible for study entry This is an exploratory study and we do not know how much time it will take for us to recruit our desired sample size. However, our maximum time frame is 1 year. After reaching our desired sample size for randomization
Primary Proportion of eligible participants who consent This is an exploratory study and we do not know how much time it will take for us to recruit our desired sample size. However, our maximum time frame is 1 year. After reaching our desired sample size for randomization
Primary Proportion of consented participants who are randomized This is an exploratory study and we do not know how much time it will take for us to recruit our desired sample size. However, our maximum time frame is 1 year. After reaching our desired sample size for randomization
Primary Proportion of randomized participants who drop out At 4-month post-randomization
Primary Level of usage of the Internet-based interventions (i.e., PRISM and SPHERE). Intervention usage will be tracked automatically At 4-month post-randomization
Primary Proportion of consented participants who complete the baseline assessment This is an exploratory study and we do not know how much time it will take for us to recruit our desired sample size. However, our maximum time frame is 1 year. After reaching our desired sample size for randomization
Primary Proportion of randomized participants who complete the 4-month post-randomization assessment At 4-month post-randomization
Primary Acceptability of the Internet-based interventions (i.e., PRISM and SPHERE) using the 8-item Client Satisfaction Questionnaire (CSQ-8) At 4-mont post-randomization
Primary Acceptability of the Internet-based interventions (i.e., PRISM and SPHERE) using the single-item Patients' Global Impression of Change Scale (PGIC) At 4-mont post-randomization
Primary Acceptability of the Internet-based interventions (i.e., PRISM and SPHERE) using the satisfaction interviews At 4-mont post-randomization
Primary Proportion of participants in the control group who show clinically significant improvement (50% or greater reduction) from baseline in number of headache days in the last 4 weeks At 4-mont post-randomization
See also
  Status Clinical Trial Phase
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Not yet recruiting NCT05943457 - Vitamin K2 Supplementation in Adult Episodic Migraine N/A
Completed NCT01211145 - Zomig - Treatment of Acute Migraine Headache in Adolescents Phase 4
Completed NCT00530517 - A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack Phase 2
Completed NCT00898677 - Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) Phase 3
Recruiting NCT06459635 - Migraine Attack Pain Phase Prediction Study
Completed NCT03971071 - A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache Phase 4
Withdrawn NCT02706015 - Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks Phase 3
Terminated NCT02375789 - Intranasal Cooling for Symptomatic Relief of Migraine N/A
Completed NCT02518464 - Ticagrelor Therapy for RefrACTORy Migraine Study Phase 4
Terminated NCT00391755 - A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches Phase 4
Completed NCT03401346 - Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults Phase 1
Completed NCT05085483 - Ketone for Migraine Prevention N/A
Completed NCT01604785 - Low-dose Propofol for Pediatric Migraine Phase 2/Phase 3
Terminated NCT00804973 - Study in Participants With Acute Migraines Headaches Phase 2
Completed NCT03341689 - Psilocybin for the Treatment of Migraine Headache Phase 1
Completed NCT01630044 - Neurostimulation Device for Treatment of Migraine Headache N/A
Active, not recruiting NCT00285402 - Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine Phase 2
Completed NCT00203255 - Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache N/A
Recruiting NCT06046508 - Migraine With Aura and Patent Foramen Ovale: Identification of Biomarkers to Select Patients In Whom Intervention Would Be Beneficial (MANET)

External Links